News at Geistlich Pharma AG

2020 · 2019 · 2018 · 2017 · 2016 · 2015 · 2014 · 2013 ·
  • The EAO – the annual congress of the European Association for Osseointegration – is important for the industry. With around 3,000 participants, it is also well visited in Rome and receives a lot of recognition. Geistlich Pharma has a strong presence at the event.
  • Between 19 and 27 September, important congresses on regenerative dental medicine were held in the three metropolises of San Francisco, Shanghai and Rome. Geistlich managed the balancing act between three continents and between scientificity and practical relevance.
  • Between 19 and 27 September, important congresses on regenerative dental medicine were held in the three metropolises of San Francisco, Shanghai and Rome. Geistlich managed the balancing act between three continents and between scientificity and practical relevance.
  • A new Geistlich News is taking shape, featuring key topics, an array of guest contributions by esteemed experts and a revised layout. For our readers, this means more information – substantiated, practical and entertaining.
  • According to a court settlement of 12 May 2014, the South Korean company Osstem must refrain from any distribution of dental products under the name B-Oss and destroy all existing products bearing this name. The name and the packaging of this product were similar to that of the long-standing market leader Geistlich Bio-Oss®.
  • Geistlich Pharma wins the 2014 prize for innovation from the Chamber of Industry and Commerce of Central Switzerland (IHZ). The IHZ rated the products Geistlich Mucograft® and Geistlich Mucograft® Seal as an outstanding achievement.
  • At its meeting on 26 August 2014, the Board of Directors of Geistlich Pharma AG reconstituted itself. Dr Andreas Geistlich is the new President of the Board of Directors.
  • Colleagues and management mourn the passing of Dr. Peter Geistlich; over many years he decisively shaped the development of the family company which is over 160 years old, enabling it to enter regenerative medicine. The obituary recalls and honours Peter Geistlich, scientist, entrepreneur and unique human being. 

  • Many manufacturers claim that their biomaterials contain no potentially harmful cell residue. A new study has shown that this is true for Geistlich products; however, other products cannot claim the same.
  • Geistlich Biomaterials brought two leading experts to the stage at the ITI World Symposium Corporate Forum in Geneva on 24-26 April 2014: Dr. Stephen Chen, Australia, and Prof. Daniel Buser, Switzerland. They represented two different concepts in bone regeneration.
PRESS CONTACT
Dr. Mirjam Kessler
Director Corporate Communications
PRESS CONTACT
Verena Vermeulen
Scientific Communication Manager